Discussion 'Cancer'
Goals and challenges of developing a patient focused myeloma center of excellence
The multiple myeloma treatment field has undergone several changes over the past 10-20 years. The average overall survival has changed from 1-3 years to 10-20 years. Yet, there is no established curative therapy for multiple myeloma. However, advanced monitoring with…
The use of CLR 131 and other targeted radiotherapeutics in pediatric cancers
Many pediatric cancers have very poor overall survival rates once they relapse or if they do not respond to initial standard treatments. Radiotherapy plays an important role in the treatment of these cancers. However, if the cancer has metastasized to…
CRISPR-edited Immune Cells Enhance Fight Against Blood Cancers
The Nobel prize winning CRISPR-Cas9 genome editing system is being explored for its potential use in cancer research and treatment. By deleting, inactivating, or otherwise modifying specific genes in cultured cells or in animal models, researchers have been able to…
UltraCAR-T Therapy – Scope & Possibilities in Multiple Myeloma Management
Ongoing clinical trials are investigating the safety and efficacy of a new type of CAR T (Chimeric antigen receptor T-cells) therapy called UltraCAR-T therapy for myeloid malignancies. Unlike current CAR T cells, which utilize viruses to attach the CAR to…
Melflufen for Myeloma: A Deep Dive
The FDA recently granted priority review to a new drug application for melflufen (INN melphalan flufenamide), in combination with dexamethasone. Melflufen is intended for use as a first choice for patients with multiple myeloma whose disease is refractory to at…